  ReviewProspects for control of emerging infectious diseases with plasmid DNA vaccinesRonald B Moss1,2  1
Vical Inc. San Diego, CA, USA 2
NexBio, Inc, San Diego CA, USA  author email corresponding author email
Journal of Immune Based Therapies and Vaccines 2009,
7:3doi:10.1186/1476-8518-7-3
|
| Published: |
7 September 2009 |
Abstract
Experiments almost 20 years ago demonstrated that injections of a sequence of DNA encoding part of a pathogen could stimulate immunity. It was soon realized that "DNA vaccination" had numerous potential advantages over conventional vaccine approaches including inherent safety and a more rapid production time. These and other attributes make DNA vaccines ideal for development against emerging pathogens. Recent advances in optimizing various aspects of DNA vaccination have accelerated this approach from concept to reality in contemporary human trials. Although not yet licensed for human use, several DNA vaccines have now been approved for animal health indications. The rapid manufacturing capabilities of DNA vaccines may be particularly important for emerging infectious diseases including the current novel H1N1 Influenza A pandemic, where pre-existing immunity is limited. Because of recent advances in DNA vaccination, this approach has the potential to be a powerful new weapon in protecting against emerging and potentially pandemic human pathogens. | 
on Google Scholar
